Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Lett. 2013 Feb 1;329(1):1-8. doi: 10.1016/j.canlet.2012.09.018. Epub 2012 Sep 29.

Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.

Author information

1
Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, United States.

Abstract

One of the most promising strategies to increase the efficacy of standard chemotherapy drugs is by combining them with low doses of histone deacetylases inhibitors (HDACis). Regarded as chemosensitizers, the addition of well-tolerated doses of HDACis to platinum-based chemotherapeutics has been proven in vitro and in vivo in recent studies for many cancer types and stages. In this review, we discuss the most commonly used combinations of histone deacetylase inhibitors and platinum based drugs in the context of their possible mechanisms, efficiency, efficacy, and related drawbacks in preclinical and clinical studies.

PMID:
23032720
PMCID:
PMC3546543
DOI:
10.1016/j.canlet.2012.09.018
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center